Pamidronate-induced SDRIFE confirmed by skin testing without cross reactivity to zoledronate
European Journal of Dermatology · 2024
DOI: 10.1684/ejd.2024.4699 ↗Kurz gefasst
Fallbericht in der Zeitschrift European Journal of Dermatology, 2024. Verfasst von Eleonore Barthalon und 3 weiteren Autor:innen. Beteiligte Einrichtung: National Reference Center on Severe cutaneous Drug Reaction Unit, Groupe Hospitalier Centre, Dermatology, Clinical Immunology Hospices civils de Lyon…. Hauptthemen laut MEDLINE: Zoledronic Acid, Bone Density Conservation Agents, Diphosphonates, Pamidronate. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
BackgroundPalmoplantar keratoderma (PPK) is a group of disorders with genetic and phenotypic heterogeneity featuring skin thickening of the palms and soles. More than 60 genes involved in various biological processes are implicated in PPK. PIK3CA is an oncogene encoding p110α, and its somatic variants contribute to a spectrum of congenital overgrowth disorders, including epidermal nevi (EN).ObjectivesTo identify the genetic basis and elucidate the pathogenesis of a patient with unilateral focal PPK.Materials & MethodsWhole-exome sequencing and Sanger sequencing combined with laser capture microdissection (LCM) were performed on genomic DNA extracted from the patient’s peripheral blood and skin lesion. Skin biopsies were taken from the lesion of the patient and normal controls for immunofluorescence. Molecular docking was performed using Alphafold2-multimer.ResultsA three-year-old girl presented with unilateral focal PPK with an identified missense variant (c.3140A>G, p.His1047Arg) in PIK3CA from affected tissue. This variant only existed in the lesional epidermis. Elevated PI3K/AKT/mTOR signalling in the affected epidermis and an increased number of Ki67-positive keratinocytes were demonstrated. Molecular docking indicated instability of the p110α-p85α dimer caused by the PIK3CA His1047Arg variant.ConclusionWe describe the first PPK case associated with a variant in PIK3CA, which expands the spectrum of PIK3CA-related disorders. Our study further underscores the importance of the PI3K/AKT/mTOR pathway in the homeostasis of skin keratinization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Reference Center on Severe cutaneous Drug Reaction Unit, Groupe Hospitalier Centre, Dermatology, Clinical Immunology Hospices civils de Lyon, Inserm U851, University Claude Bernard Lyon 1, Lyon, France.
- Immuno-allerglogy department, Chu Brugmann, ULB, Brunelle, Belgium.
Zitieren
APA
Barthalon, E., Dupire, G., Calugareanu, A., & Said, B. B. (2024). Pamidronate-induced SDRIFE confirmed by skin testing without cross reactivity to zoledronate. European Journal of Dermatology. https://doi.org/10.1684/ejd.2024.4699
Vancouver
Barthalon E, Dupire G, Calugareanu A, Said BB. Pamidronate-induced SDRIFE confirmed by skin testing without cross reactivity to zoledronate. European Journal of Dermatology. 2024. doi:10.1684/ejd.2024.4699
BibTeX
@article{Barthalon2024,
author = {Barthalon, Eleonore and Dupire, Gwendy and Calugareanu, Andreea and Said, Benoit Ben},
title = {Pamidronate-induced SDRIFE confirmed by skin testing without cross reactivity to zoledronate},
journal = {European Journal of Dermatology},
year = {2024},
doi = {10.1684/ejd.2024.4699}
}
EUVIMED